Claims
- 1. A purified and isolated non-naturally occurring RNA ligand to transforming growth factor β1 (TGFβ1) wherein said ligand is selected from the group consisting of the sequences set forth in Table 22 (SEQ ID NOS:194-215).
- 2. A complex comprised of a TGFβ1 nucleic acid ligand and a non-immunogenic, high molecular weight compound or lipophilic compound, wherein said ligand is selected from the group consisting of the sequences set forth in claim 1.
- 3. The complex of claim 2 further comprising a linker between said ligand and said non-immunogenic, high molecular weight compound or lipophilic compound.
- 4. The complex of claim 2 wherein said non-immunogenic, high molecular weight compound is polyalkylene glycol.
- 5. The complex of claim 4 wherein said polyalkylene glycol is polyethylene glycol (PEG).
- 6. The complex of claim 5 wherein said PEG has a molecular weight of about between 10-80 K.
- 7. The complex of claim 6 wherein said PEG has a molecular weight of about 20-45 K.
- 8. The complex of claim 7 wherein said complex is: LIGAND=5′mGmGmGrUrGrCrCrUrUrUrUrGrCrCrUmAmGmGrUrUmGrUmGmArUrU rUmGrUmAmArCrCrUrUrCrUrGrCrCrCmA3′-3′rU (SEQ ID NO:210)wherein r prefix indicates unmodified ribonucleoside, m prefix indicates 2′-O-methyl substituted ribonucleotide.
- 9. A complex comprised of a TGFβ2 nucleic acid ligand, and a non-immunogenic, high molecular weight compound or lipophilic compound, wherein said ligand is selected from the group consisting of the sequences set forth in Tables 5, 7, 8, 11, 13, 14, 16-19, and FIG. 9 (SEQ ID NOS:21-121 and 128-193).
- 10. The complex of claim 9 further comprising a linker between said ligand and said non-immunogenic, high molecular weight compound or lipophilic compound.
- 11. The complex of claim 9 wherein said non-immunogenic, high molecular weight compound is a polyalkylene glycol.
- 12. The complex of claim 11 wherein said polyalkylene glycol is polyethylene glycol (PEG).
- 13. The complex of claim 12 wherein said PEG has a molecular weight of about between 10-80 K.
- 14. The complex of claim 13 wherein said PEG has a molecular weight of about 20-45 K.
RELATED APPLICATIONS
This application is a continuation of U.S. patent application Ser. No. 09/363,939, filed Jul. 29, 1999, entitled “High Affinity TGFβ Nucleic Acid Ligands and Inhibitors,” which is a continuation-in-part of U.S. patent application Ser. No. 09/046,247, now U.S. Pat. No. 6,124,449, filed Mar. 23, 1998, entitled “High Affinity TGFβ Nucleic Acid Ligands and Inhibitors,” which is a continuation-in-part of U.S. patent application Ser. No. 08/458,424, now U.S. Pat. No. 5,731,424, filed Jun. 2, 1995, entitled “High Affinity TGFβ Nucleic Acid Ligands and Inhibitors,”, which is a continuation-in-part of U.S. patent application Ser. No. 07/714,131, now U.S. Pat. No. 5,475,096, filed Jun. 10, 1991, entitled “Nucleic Acid Ligands,” U.S. patent application Ser. No. 07/931,473, now U.S. Pat. No. 5,270,163, filed Aug. 17, 1992, entitled “Methods for Identifying Nucleic Acid Ligands,” U.S. patent application Ser. No. 07/964,624, now U.S. Pat. No. 5,496,938, filed Oct. 21, 1992, entitled “Nucleic Acid Ligands to HIV-RT and HIV-1 Rev” and U.S. patent application Ser. No. 08/117,991, filed Sep. 8, 1993, entitled “High Affinity Nucleic Acid Ligands Containing Modified Nucleotides,” now abandoned. U.S. patent application Ser. No. 07/714,131 is a continuation-in-part of U.S. patent application Ser. No. 07/536,428, filed Jun. 11, 1990, entitled “Systematic Evolution of Ligands by EXponential Enrichment,” now abandoned. This application is also a continuation-in-part of U.S. patent application Ser. No. 08/434,465, now U.S. Pat. No. 6,011,020, filed May 4, 1995 entitled “Nucleic Acid Ligand Complexes.”
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
5723323 |
Kauffman et al. |
Mar 1998 |
A |
5731424 |
Toothman et al. |
Mar 1998 |
A |
5859228 |
Janjic et al. |
Jan 1999 |
A |
6011020 |
Gold et al. |
Jan 2000 |
A |
6124449 |
Gold et al. |
Sep 2000 |
A |
6346611 |
Pagratis et al. |
Feb 2002 |
B1 |
Foreign Referenced Citations (7)
Number |
Date |
Country |
2 183 661 |
Jun 1987 |
GB |
WO 8906694 |
Jul 1989 |
WO |
WO 9119813 |
Dec 1991 |
WO |
WO 9214843 |
Sep 1992 |
WO |
WO 9638579 |
Dec 1996 |
WO |
WO 9818480 |
May 1998 |
WO |
WO 9948904 |
Sep 1999 |
WO |
Non-Patent Literature Citations (15)
Entry |
Joyce (1989) Gene 82:83. |
Joyce & Inoue (1989) Nucleic Acids Research 17:711. |
Ellington & Szostak (1990) Abstracts of papers presented at the 1990 meeting on RNA Processing, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 84. |
Kinzler & Vogelstein (1989) Nucleic Acids Research 17:3645. |
Kramer et al. (1974) J. Mol. Biol. 89:719. |
Levisohn & Spiegelman (1969) Proc. Natl. Acad. Sci. USA 63:805. |
Levisohn & Spiegelman (1968) Proc. Natl. Acad. Sci. USA 60:866. |
Oliphant et al. (1989) Mol. Cell. Biol. 9:2944. |
Oliphant & Struhl (1988) Nucleic Acids Research 16:7673. |
Oliphant & Struhl (1987) Methods in Enzymology 155:568. |
Oliphant et al. (1986) Gene 44:177. |
Robertson & Joyce (1990) Nature 344:467. |
Thiesen & Bach (1990) Nucleic Acids Research 18:3203. |
Szostak, “Structure and Activity of Ribozymes,” in Redesigning the Molecules of Life, (S.A. Benner ed.) Springer-Verlag Berline Heidelberg, pp. 87-113 (1988). |
Database EMBL Online (1997) Database accession: AAT57879, XP-002228934. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09/363939 |
Jul 1999 |
US |
Child |
09/791301 |
|
US |
Continuation in Parts (8)
|
Number |
Date |
Country |
Parent |
09/046247 |
Mar 1998 |
US |
Child |
09/363939 |
|
US |
Parent |
08/458424 |
Jun 1995 |
US |
Child |
09/046247 |
|
US |
Parent |
08/434465 |
May 1995 |
US |
Child |
08/458424 |
|
US |
Parent |
08/117991 |
Sep 1993 |
US |
Child |
08/434465 |
|
US |
Parent |
07/964624 |
Oct 1992 |
US |
Child |
08/117991 |
|
US |
Parent |
07/931473 |
Aug 1992 |
US |
Child |
07/964624 |
|
US |
Parent |
07/714131 |
Jun 1991 |
US |
Child |
07/931473 |
|
US |
Parent |
07/536428 |
Jun 1990 |
US |
Child |
07/714131 |
|
US |